Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2019 1
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P. Kvarnhammar AM, et al. Among authors: smith ke. J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8. J Immunother Cancer. 2019. PMID: 30975201 Free PMC article.
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A, Nilsson A, Thagesson M, Werchau D, Enell Smith K, Ellmark P. Deronic A, et al. Among authors: enell smith k. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. doi: 10.1007/s00262-021-02932-5. Epub 2021 May 5. Cancer Immunol Immunother. 2021. PMID: 33948686 Free PMC article.
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K, Fritzell S, Nilsson A, Barchan K, Rosén A, Schultz L, Varas L, Säll A, Rose N, Håkansson M, von Schantz L, Ellmark P. Enell Smith K, et al. Cancer Immunol Immunother. 2023 Dec;72(12):4145-4159. doi: 10.1007/s00262-023-03548-7. Epub 2023 Oct 5. Cancer Immunol Immunother. 2023. PMID: 37796298 Free PMC article.